Trial Information
Summary: Anemia- Darbepoetin Alfa Treatment for Chronic Kidney Disease
People with chronic kidney disease currently receiving Aranesp®
(darbepoetin alfa) or EPO/Epogen® (erythropoietin) to treat anemia
are asked to participate in a research study being conducted by
North Shore University Hospital.
You may be eligible to participate in this study if
you:
- Are male or female at least 18 years of age.
- Have chronic kidney disease.
- Are currently receiving Aranesp® (darbepoetin alfa) or
EPO/Epogen® (erythropoietin).
You may not participate in this study if
you:
- Are pregnant or intend to become pregnant during the
study.
- Have had major surgery in the last 3 months.
- Have had androgen therapy in the last 8 weeks.
- Have participated in another research study within the last 30
days.
For more information,
|
Contact:
Maria Marotta-Kollarus, Study Coordinator
Biomedical Research Alliance of New York
North Shore University Hospital
Julia and Israel Waldbaum Dialysis Center
Division of Nephrology and Hypertension
100 Community Drive
Great Neck, NY 11021
Telephone: 516-465-8841
Fax: 516-465-8202
Email:
|
|

If you would like to learn more about participating in this study, please send an e-mail message using the form below.
Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.
This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.
Trial listings updated: June 1, 2008 at 5:44:20 AM